Rani Therapeutics Holdings, Inc. - 8-K Filing

Rani Therapeutics reports Q3 2026 contract revenue of $1.7M and expects cash runway through end of 2027. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $RANI

Read the full article at SEC EDGAR

More Regulatory news